Skip to content
Politically.com Search all
Menu

2025 · 3rd Quarter (July 1 - Sep 30)

EISAI INC.

Filed by EISAI INC..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 20, 2025
Income
Not reported
Expenses
$620,000.00
Registrant
EISAI INC.
Filing UUID
ef97ac67-0d60-4858-b876-a6635509526e
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; Pharmacy benefit managers (PBM) reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Literal federal measure citations: S.891

MMM · Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Issues related to pharmaceutical intellectual property.

TAX · Taxation/Internal Revenue Code

Issues related to tax reform. Research and Development tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.

Literal federal measure citations: H.R.1

TRD · Trade (domestic/foreign)

Issues related to supply chain and tariffs. Section 232 tariff investigation on branded pharmaceuticals.

BUD · Budget/Appropriations

H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.

Literal federal measure citations: H.R.1

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.